H.I.G. Ventures

H.I.G. Ventures partners with entrepreneurs to provide the capital, expertise and relationships necessary to build market-leading businesses. With over $550 million in dedicated venture capital under management, the firm's team invests nationally in early to mid-stage information technology and life sciences businesses. H.I.G. Ventures is the venture capital affiliate of H.I.G. Capital, a leading private and public equity investment firm with over $2.5 billion of capital under management and offices in Atlanta, Boston, Miami and San Francisco.

For more information, visit

KBL Ventures

KBL is a venture capital firm dedicated to investing in early stage and emerging growth healthcare companies. Our goal is to identify companies that are run by seasoned management teams and that have the potential to create long term value. Major areas of investment include life sciences, medical devices, healthcare services and medical information technology. Within the medical device area, we seek companies addressing large, unmet medical needs with demonstrated clinical benefit.

KBL brings a team of investment professionals with prior experiences as senior executives, clinical practitioners and venture capitalists. While we are capable of bringing managerial and technical expertise to an emerging company, we are also able to draw upon a rich network of contacts across multiple disciplines to foster the growth and development of our portfolio companies. We pride ourselves on developing lasting relationships with our entrepreneurs and look to cultivate a professionally and personally rewarding experience for all involved.

For more information, visit

Oxford Biosciences Partners

The objective of Oxford Bioscience Partners is to generate long-term capital gains for both the investors in the Fund and the entrepreneurs that we support. To meet this goal, we invest in businesses capable of improving the diagnosis and treatment of disease, as well as the overall delivery of healthcare.

The General Partners of Oxford Bioscience Partners have achieved considerable success and above average returns in the bioscience/ healthcare industries over the past 15 years through investments in more than 100 companies.

Additionally, the General Partners, collectively, have served on the Board of Directors of more than 50 biotechnology and healthcare companies and have assumed the position of Chairman or President for more than 14 bioscience concerns. They have extensive operating management experience in the U.S. and abroad and have played a key role in the founding of a number of successful bioscience ventures.

For more information, visit

SV Life Sciences Advisors

SV Life Sciences™ ('SVLS'), known previously as Schroder Ventures Life Sciences, have invested in the life sciences industry since the early 1980's and to date have backed over 100 companies worldwide. SVLS was established in 1993 and currently has offices in Boston, London and San Francisco, which allows us to take advantage of the global nature of the life sciences opportunity. The SVLS team is comprised of 22 professionals, with extensive life sciences, investment, strategic, operational, scientific and clinical experience.

SVLS advises two private equity funds with total commitments of approximately $410m, focused on providing seed, start-up, early stage and expansion capital to life sciences companies in Europe, the US and Asia. In addition, SVLS advises the International Biotechnology Trust (IBT) plc, a publicly quoted investment trust listed on the London Stock Exchange (IBT.L), with a total net asset value of approximately £130m (as at 31 December 2001). The majority of IBT's investments are in quoted companies.

Funds advised by SVLS are able to invest in all stages in the development of a life science company. SVLS provides hands-on scientific, advisory as well as financial support to its portfolio companies.

For more information, visit

Aurora Funds

The Aurora Funds is a venture capital firm that provides capital, connections and strategic guidance to entrepreneurs with early-stage healthcare and information technology companies. Founded in 1994, Aurora manages over $230 million in five venture funds. The firm's six investment professionals have over 100 years of combined venture capital investing and operational experience. The Aurora team has managed investments in over 60 companies, resulting in numerous successful IPO's and M&A transactions.

Aurora typically is a lead or co-lead investor in seed and early-stage financing opportunities located primarily in the Southeastern and mid-Atlantic United States. The firm's initial investment size ranges from $50,000 in a seed investment to as much as $2.5 million in a first round financing. Aurora has the capacity to invest a total of between $4 million and $8 million across multiple rounds of financing as the company matures.

For more information, visit

Accuitive Medical Ventures

Accuitive Medical Ventures (AMV) is a venture capital firm with offices in Atlanta, GA, Newport Beach, CA, and Rochester, MN. AMV is in business to finance and help develop early and expansion stage medical device and technology companies. In conjunction with The Innovation Factory (, the Atlanta based medical device incubator, AMV has the resources and the experience to create long-term value for medical technology inventors and innovators.

The AMV team has significant executive management, operating and board experience, as well as demonstrated expertise in sourcing, financing and exiting successful medical device companies. They have collectively co-founded 15 companies, raised over $250 million in private equity capital and have participated in private and public equity financings of well over $700 million while creating over $1 billion in shareholder value in their careers.

For more information, visit

Kestrel Venture Management

Kestrel Venture Management (formerly Corning Venture Management) provides equity capital and support to small companies with exceptional growth prospects. Since inception, our objective has been to achieve superior returns for our investors while providing entrepreneurs the opportunity to build significant and successful businesses.

In addition to providing capital to fuel a portfolio company's growth, Kestrel Venture Management's team draws on its over four decades of cumulative experience to render guidance to the management of growing companies, thus enhancing the likelihood of mutual success. With this in mind, Kestrel seeks to establish and maintain a close working relationship with the management of each portfolio company.

For more information, visit

Fletcher Spaght Ventures

Fletcher Spaght Ventures invests in healthcare, life science and high technology companies with growth potential. Fletcher Spaght Ventures leverages the strategy consulting arm of the firm, Fletcher Spaght Inc., to assess the potential for each investment opportunity. Post investment, the Fletcher Spaght team contributes their deep industry knowledge as well as their general strategic and analytical expertise to assist portfolio companies to achieve their potential and to enhance value.

For more information, visit